​​​​​​​PsA Treatment Options Expand - Top-Institutions - MDSpire

​​​​​​​PsA Treatment Options Expand

Phase 3 POETYK trial results support FDA approval of deucravacitinib for adults with active PsA.

  • By

  • Kathryn Wighton

  • March 9, 2026

  • 3 min

Share

Top Institutions in Rheumatology

Brief introduction explaining scope and methodology.

  • #1

    Hospital for Special Surgery
    Hospital for Special Surgery

    New York, NY

    Key Differentiators

    • Rheumatology
    • Immunology
    • Clinical Trials

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Rheumatology
    • Clinical Immunology
    • Translational Research

  • #3

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Rheumatology
    • Immunology
    • Clinical Trials

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Rheumatology
    • Autoimmune Disease Research
    • Clinical Trials

Original Source(s)

​​​​​​​PsA Treatment Options Expand

  • by Kathryn Wighton

  • March 9, 2026

Related Content

Sex Differences Seen in Immune Cells

Single-cell analysis identified sex-biased immune-cell composition, gene expression, and genetic regulation in unstimulated blood immune cells

Case report : Early-Onset Juvenile Psoriatic Arthritis Presenting at 15 Months: A Diagnostic Challenge in Infancy

SSc May Be Linked to Subtle Cognitive Changes

Cross-sectional study finds domain-specific differences and higher anxiety without global impairment.